Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years

Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Julia Stowe; Elise Tessier; Ruth Simmons; Mary Ramsay

doi:10.1093/cid/ciab881

Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years

Clin Infect Dis. 2024 Feb 17;78(2):349-351. doi: 10.1093/cid/ciab881.

Authors

Jamie Lopez Bernal^{1

2

3}, Nick Andrews^{1

2}, Charlotte Gower¹, Julia Stowe¹, Elise Tessier¹, Ruth Simmons¹, Mary Ramsay^{1

2}

Affiliations

¹ Public Health England, London, United Kingdom.
² NIHR Health Protection Research Unit in Vaccines and Immunisation, London School of Hygiene and Tropical Medicine, London, United Kingdom.
³ NIHR Health Protection Research Unit in Respiratory Infections, Imperial College London, London, United Kingdom.

PMID: 37758203
DOI: 10.1093/cid/ciab881

Abstract

We estimated the risk of death from coronavirus disease 2019 in vaccinated compared with unvaccinated patients. The risk of death was reduced 44% after 1 dose of the Pfizer-BioNTech BNT162b2 vaccine, 55% after 1 dose of the Oxford-Astrazeneca ChAdOx1 vaccine, and 69% after 2 doses of the BNT162b2 vaccine. This is above the protection provided against infection.

MeSH terms

Adenoviridae / genetics
Adenovirus Vaccines*
Adult
BNT162 Vaccine
COVID-19* / prevention & control
Humans
RNA, Messenger
Vaccines*
mRNA Vaccines

Substances

Adenovirus Vaccines
BNT162 Vaccine
mRNA Vaccines
Vaccines
RNA, Messenger